224 results on '"Haass-Koffler, Carolina L."'
Search Results
2. Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial
3. Yohimbine as a pharmacological probe for alcohol research: a systematic review of rodent and human studies
4. Development and use of a high-throughput screen to identify novel modulators of the corticotropin releasing factor binding protein
5. Neuroscience targets and human studies: future translational efforts in the stress system
6. An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder
7. Disruption of circadian rhythms promotes alcohol use: a systematic review.
8. Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy
9. Evaluating the Readability of Online Patient Facing Resources for Alcohol Use Disorder
10. Opioid Craving in Human Laboratory Settings: a Review of the Challenges and Limitations
11. The corticotropin releasing factor binding protein: A strange case of Dr. Jekyll and Mr. Hyde in the stress system?
12. Towards Personalized Treatments for Alcohol Use Disorder: a Focus on α1-blockade
13. Evaluating the readability of online patient-facing resources for alcohol use disorder
14. Translational Research in the Neurobiological Mechanisms of Alcohol and Substance Use Disorders
15. Opioid use and stigma: The role of gender, language and precipitating events
16. A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers
17. Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin
18. Noradrenergic targets for the treatment of alcohol use disorder
19. Utilizing precision medicine to treat alcohol use disorder: A commentary on the α1 receptor antagonist
20. COVID-19-Related Stressors and Clinical Mental Health Symptoms in a Northeast US Sample
21. Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a translational crossover randomized trial
22. Mifepristone as a pharmacological intervention for stress‐induced alcohol craving: A human laboratory study.
23. Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: Exploratory findings
24. The multitarget FAAH inhibitor/D3 partial agonist ARN15381 decreases nicotine self-administration in male rats
25. The Amygdala Noradrenergic System Is Compromised With Alcohol Use Disorder
26. Disruption of Circadian Rhythms Promotes Alcohol Use
27. Corticotropin Releasing Factor Binding Protein as a Novel Target to Restore Brain Homeostasis: Lessons Learned From Alcohol Use Disorder Research
28. Association of Substance Use With Behavioral Adherence to Centers for Disease Control and Prevention Guidelines for COVID-19 Mitigation: Cross-sectional Web-Based Survey
29. An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder
30. Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder
31. Pharmacological Approaches to Reducing Craving in Patients with Alcohol Use Disorders
32. Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial
33. Effects of Idazoxan on Alcohol Pharmacokinetics and Intoxication: A Preliminary Human Laboratory Study
34. Relationship Between the Thyroid Axis and Alcohol Craving
35. Randomized controlled trials for alcohol use disorder during the COVID-19 pandemic
36. Association of Substance Use With Behavioral Adherence to Centers for Disease Control and Prevention Guidelines for COVID-19 Mitigation: Cross-sectional Web-Based Survey (Preprint)
37. Pharmacotherapy for alcoholic patients with alcoholic liver disease
38. Ondansetron Reduces Naturalistic Drinking in Nontreatment-Seeking Alcohol-Dependent Individuals with the LL 5′-HTTLPR Genotype: A Laboratory Study
39. Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study
40. Andrographis paniculata and Its Main Bioactive Ingredient Andrographolide Decrease Alcohol Drinking and Seeking in Rats Through Activation of Nuclear PPARγ Pathway
41. Some Alcohol-Related Consequences for Women May Signal an Escape from Interpersonal Violence
42. New Microglial Mechanisms Revealed in Alcohol Use Disorder: How Does That Translate?
43. Brief Report: Relationship Between Cotinine Levels and Peripheral Endogenous Concentrations of Oxytocin, β-Endorphin, and Orexin in Individuals With Both Alcohol and Nicotine Use Disorders.
44. Differences in Sociodemographic and Alcohol‐Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder
45. A Combined Alcohol and Smoking Cue-Reactivity Paradigm in People Who Drink Heavily and Smoke Cigarettes: Preliminary Findings
46. Translational dynamics of alcohol tolerance of preclinical models and human laboratory studies.
47. Brief Report: Relationship Between Cotinine Levels and Peripheral Endogenous Concentrations of Oxytocin, β‐Endorphin, and Orexin in Individuals With Both Alcohol and Nicotine Use Disorders
48. Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary
49. Alcohol Tolerance in Human Laboratory Studies for Development of Medications to treat Alcohol Use Disorder
50. Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.